Tichatschek E, Zielinski C C, Müller C, Sevelda P, Kubista E, Czerwenka K, Spona J, Wolf H, Eibl M M
Dept of Medicine, University Hospital, Vienna, Austria.
Cancer Immunol Immunother. 1988;27(3):278-82. doi: 10.1007/BF00205452.
Unstimulated IFN- and IL2-stimulated (NK) cell activities were investigated in patients with breast cancer who had received either local radiotherapy alone or adjuvant chemotherapeutic treatment with CMF combined with radiotherapy 12 to 18 months previously. When tested against the primarily NK-sensitive K562 cell line, patients who had received adjuvant chemotherapeutic treatment with CMF were shown to have a significantly decreased unstimulated and IFN-stimulated NK cell activity, as compared to both patients after radiotherapy only (P less than 0.002) and P less than 0.005, respectively) and healthy control persons (P less than 0.05). The former group of patients also had a significantly decreased IFN-stimulated NK cell activity, when tested against the primarily NK-insensitive Chang hepatoma cell line, as compared to patients after radiotherapy only (P less than 0.005) and healthy controls (P less than 0.05). Moreover, patients after radiotherapy only proved to have a significantly increased unstimulated (P less than 0.01) and IFN-stimulated NK cell activity (K562: P less than 0.05; Chang hepatoma cell line: P less than 0.05), as compared to healthy control individuals. In contrast, no difference in IL2-stimulated NK cell activity was detected. The investigation for the expression of CD3 and/or Leu 19 antigens as phenotypic markers of cells with non-MHC restricted cytotoxicity showed a significantly lower percentage of cells with the CD3+ phenotype in patients with breast cancer, irrespective of the chosen post-operative treatment, as compared to healthy controls (P less than 0.01). Finally, patients with breast cancer who had received radiotherapy only had a significant trend towards an increased percentage of CD3+/Leu 19+ PMNC, as compared to both patients after CMF treatment (P less than 0.05) and healthy controls (P less than 0.025). We conclude that patients with breast cancer vary on a long-term basis in their NK activity and in the phenotype of their PMNC depending on their post-operative adjuvant management.
对12至18个月前接受过单纯局部放疗或CMF联合放疗的辅助化疗的乳腺癌患者的未刺激的干扰素和白细胞介素2刺激的（自然杀伤细胞）活性进行了研究。当用主要对自然杀伤细胞敏感的K562细胞系进行检测时，与仅接受放疗的患者（分别为P小于0.002和P小于0.005）以及健康对照者（P小于0.05）相比，接受CMF辅助化疗的患者显示出未刺激的和干扰素刺激的自然杀伤细胞活性显著降低。当用主要对自然杀伤细胞不敏感的张氏肝癌细胞系进行检测时，与仅接受放疗的患者（P小于0.005）和健康对照者（P小于0.05）相比，前一组患者的干扰素刺激的自然杀伤细胞活性也显著降低。此外，与健康对照个体相比，仅接受放疗后的患者显示出未刺激的自然杀伤细胞活性显著增加（P小于0.01）以及干扰素刺激的自然杀伤细胞活性增加（K562细胞系：P小于0.05；张氏肝癌细胞系：P小于0.05）。相反，未检测到白细胞介素2刺激的自然杀伤细胞活性有差异。对作为非主要组织相容性复合体限制性细胞毒性细胞表型标志物的CD3和/或Leu 19抗原表达的研究表明，与健康对照者相比（P小于0.01）, 无论选择何种术后治疗，乳腺癌患者中具有CD3+表型的细胞百分比显著降低。最后, 与接受CMF治疗的患者（P小于0.05）和健康对照者（P小于0.025）相比，仅接受放疗的乳腺癌患者的CD3+/Leu 19+外周血单个核细胞百分比有显著增加的趋势。我们得出结论，乳腺癌患者根据其术后辅助治疗情况，其自然杀伤细胞活性和外周血单个核细胞表型在长期内存在差异。
